Olon S.p.a.

Barbara Novo

Giorgio Bertolini

Mara Sada

Jacopo Bonanomi

Mattia Bertolotti

Stella Defiore

Francesco Calogero

Valentina Grande

Gabriele Ferretti

Stella De Fiore

Simona Trabace

Matteo Fusari

The present invention relates to a process for the preparation of Apalutamide of formula (A) Apalutamide is a latest-generation androgen receptor inhibitor, used to treat non-metastatic castration-resistant prostate cancer.

Process for the preparation of apalutamide

Disclosed is a process for the synthesis of pimavanserin base with a high yield and purity, which comprises: a) converting tert-butyl-N-[(4-propan-2-yloxyphenyl)methyl]carbamate (Formula (I)) to 1-(isocyanatomethyl)-4-propan-2-yloxybenzene of formula (II) b) adding N-[(4-fluorophenyl)methyl]-1-methylpiperidin-4-amine (Formula (IV)) to the solution obtained in a) to give pimavanserin base, and c) purifying the pimavanserin base obtained in step b). 

Method for the preparation of pimavanserin base

Disclosed is a process for the preparation of Cangrelor in salt form by preparation and subsequent hydrolysis of an intermediate of formula (IV): 

Efficient method for the preparation of Cangrelor

Disclosed are a novel crystalline form and an amorphous form of Olaparib, and the process for their preparation.

Crystalline and amorphous forms of Olaparib

Disclosed is a novel process for the synthesis of tofacitinib citrate on an industrial scale with high yields and purity starting with cis-(1-benzyl-4-methyl-piperidin-3-yl)methylamine bis-hydrochloride racemate (intermediate VIII), which comprises: 

Growing community of inventors

Rodano, Italy

Barbara Novo